[Translation] An open-label phase I clinical study of the safety and preliminary efficacy of autologous T cell injection targeting CD30 chimeric antigen receptor gene modification in patients with CD30+ relapsed/refractory hematological tumors
评价靶向CD30嵌合抗原受体基因修饰的自体T细胞注射液治疗CD30+复发/难治性血液肿瘤患者的安全性。
[Translation] To evaluate the safety of autologous T cell injection targeting CD30 chimeric antigen receptor gene modification in the treatment of patients with CD30+ relapsed/refractory hematological tumors.